Nuvectis Pharma (NVCT) Change in Account Payables (2023 - 2026)

Nuvectis Pharma has reported Change in Account Payables for 4 years, with the latest figure at -$1.6 million in Q1 2026.

• Quarterly Change in Account Payables fell 419.64% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 38.12% YoY) and the FY2025 annual result came in at $3.8 million, up 1483.15% from the prior year.
• Change in Account Payables eased to -$1.6 million in Q1 2026 per NVCT's latest filing, from -$165000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $2.0 million in Q2 2025 and troughed at -$1.6 million in Q1 2026.
• A 4-year average of $137307.7 and a median of $87000.0 in 2024 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2025 and 2026: Change in Account Payables surged 2181.61% in 2025, then slumped 419.64% in 2026.
• Over 4 years, Change in Account Payables stood at -$721000.0 in 2023, then jumped by 132.87% to $237000.0 in 2024, then plunged by 169.62% to -$165000.0 in 2025, then slumped by 856.97% to -$1.6 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$1.6 million, -$165000.0, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.